Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Potentiating NK cell activity by combination of Rosuvastatin and Difluoromethylornithine for effective chemopreventive efficacy against Colon Cancer.

Janakiram NB, Mohammed A, Bryant T, Zhang Y, Brewer M, Duff A, Biddick L, Singh A, Lightfoot S, Steele VE, Rao CV.

Sci Rep. 2016 Nov 14;6:37046. doi: 10.1038/srep37046.

2.

Methionine-restricted diet inhibits growth of MCF10AT1-derived mammary tumors by increasing cell cycle inhibitors in athymic nude mice.

Hens JR, Sinha I, Perodin F, Cooper T, Sinha R, Plummer J, Perrone CE, Orentreich D.

BMC Cancer. 2016 Jun 3;16:349. doi: 10.1186/s12885-016-2367-1. Erratum in: BMC Cancer. 2016;16:474.

3.

Phase IIB Randomized Study of Topical Difluoromethylornithine and Topical Diclofenac on Sun-Damaged Skin of the Forearm.

Jeter JM, Curiel-Lewandrowski C, Stratton SP, Myrdal PB, Warneke JA, Einspahr JG, Bartels HG, Yozwiak M, Bermudez Y, Hu C, Bartels P, Alberts DS.

Cancer Prev Res (Phila). 2016 Feb;9(2):128-34. doi: 10.1158/1940-6207.CAPR-15-0232. Epub 2015 Dec 28.

4.

Skin Carcinogenesis Studies Using Mouse Models with Altered Polyamines.

Nowotarski SL, Feith DJ, Shantz LM.

Cancer Growth Metastasis. 2015 Aug 9;8(Suppl 1):17-27. doi: 10.4137/CGM.S21219. eCollection 2015. Review.

5.

Molecular cancer prevention: Current status and future directions.

Maresso KC, Tsai KY, Brown PH, Szabo E, Lippman S, Hawk ET.

CA Cancer J Clin. 2015 Sep-Oct;65(5):345-83. doi: 10.3322/caac.21287. Epub 2015 Aug 18. Review.

6.

A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma.

Saulnier Sholler GL, Gerner EW, Bergendahl G, MacArthur RB, VanderWerff A, Ashikaga T, Bond JP, Ferguson W, Roberts W, Wada RK, Eslin D, Kraveka JM, Kaplan J, Mitchell D, Parikh NS, Neville K, Sender L, Higgins T, Kawakita M, Hiramatsu K, Moriya SS, Bachmann AS.

PLoS One. 2015 May 27;10(5):e0127246. doi: 10.1371/journal.pone.0127246. eCollection 2015.

7.

Polyamine metabolism is sensitive to glycolysis inhibition in human neuroblastoma cells.

Ruiz-Pérez MV, Medina MÁ, Urdiales JL, Keinänen TA, Sánchez-Jiménez F.

J Biol Chem. 2015 Mar 6;290(10):6106-19. doi: 10.1074/jbc.M114.619197. Epub 2015 Jan 15.

8.

Eflornithine (DFMO) prevents progression of pancreatic cancer by modulating ornithine decarboxylase signaling.

Mohammed A, Janakiram NB, Madka V, Ritchie RL, Brewer M, Biddick L, Patlolla JM, Sadeghi M, Lightfoot S, Steele VE, Rao CV.

Cancer Prev Res (Phila). 2014 Dec;7(12):1198-209. doi: 10.1158/1940-6207.CAPR-14-0176. Epub 2014 Sep 23.

9.

Inhibiting cycloxygenase and ornithine decarboxylase by diclofenac and alpha-difluoromethylornithine blocks cutaneous SCCs by targeting Akt-ERK axis.

Arumugam A, Weng Z, Talwelkar SS, Chaudhary SC, Kopelovich L, Elmets CA, Afaq F, Athar M.

PLoS One. 2013 Nov 8;8(11):e80076. doi: 10.1371/journal.pone.0080076. eCollection 2013.

10.

Polyamine depletion inhibits the autophagic response modulating Trypanosoma cruzi infectivity.

Vanrell MC, Cueto JA, Barclay JJ, Carrillo C, Colombo MI, Gottlieb RA, Romano PS.

Autophagy. 2013 Jul;9(7):1080-93. doi: 10.4161/auto.24709. Epub 2013 May 6.

11.

Polyamines and cancer: implications for chemotherapy and chemoprevention.

Nowotarski SL, Woster PM, Casero RA Jr.

Expert Rev Mol Med. 2013 Feb 22;15:e3. doi: 10.1017/erm.2013.3. Review.

12.

Targeted expression of ornithine decarboxylase antizyme prevents upper aerodigestive tract carcinogenesis in p53-deficient mice.

Feith DJ, Pegg AE, Fong LY.

Carcinogenesis. 2013 Mar;34(3):570-6. doi: 10.1093/carcin/bgs377. Epub 2012 Dec 7.

13.

Difluoromethylornithine: the proof is in the polyamines.

Jeter JM, Alberts DS.

Cancer Prev Res (Phila). 2012 Dec;5(12):1341-4. doi: 10.1158/1940-6207.CAPR-12-0429.

14.

A phase III skin cancer chemoprevention study of DFMO: long-term follow-up of skin cancer events and toxicity.

Kreul SM, Havighurst T, Kim K, Mendonça EA, Wood GS, Snow S, Borich A, Verma A, Bailey HH.

Cancer Prev Res (Phila). 2012 Dec;5(12):1368-74. doi: 10.1158/1940-6207.CAPR-12-0233. Epub 2012 Oct 11.

15.

S-adenosylmethionine decarboxylase overexpression inhibits mouse skin tumor promotion.

Shi C, Cooper TK, McCloskey DE, Glick AB, Shantz LM, Feith DJ.

Carcinogenesis. 2012 Jul;33(7):1310-8. doi: 10.1093/carcin/bgs184. Epub 2012 May 19.

16.

Spermine synthase overexpression in vivo does not increase susceptibility to DMBA/TPA skin carcinogenesis or Min-Apc intestinal tumorigenesis.

Welsh PA, Sass-Kuhn S, Prakashagowda C, McCloskey D, Feith D.

Cancer Biol Ther. 2012 Apr;13(6):358-68. doi: 10.4161/cbt.19241. Epub 2012 Apr 1.

17.

DFMO: targeted risk reduction therapy for colorectal neoplasia.

Laukaitis CM, Gerner EW.

Best Pract Res Clin Gastroenterol. 2011 Aug;25(4-5):495-506. doi: 10.1016/j.bpg.2011.09.007. Review.

18.

Knockdown of antizyme inhibitor decreases prostate tumor growth in vivo.

Olsen RR, Chung I, Zetter BR.

Amino Acids. 2012 Feb;42(2-3):549-58. doi: 10.1007/s00726-011-1032-x. Epub 2011 Sep 11.

19.

Evidence of a role for antizyme and antizyme inhibitor as regulators of human cancer.

Olsen RR, Zetter BR.

Mol Cancer Res. 2011 Oct;9(10):1285-93. doi: 10.1158/1541-7786.MCR-11-0178. Epub 2011 Aug 17. Review.

20.

Biomarkers in exploring the frontiers of diagnosis, prognosis, and therapy of Barrett's esophagus.

Yachimski P, Peek RM Jr.

Cancer Prev Res (Phila). 2011 Jun;4(6):783-6. doi: 10.1158/1940-6207.CAPR-11-0204.

Supplemental Content

Support Center